globenewswire news

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-08-14T20:05:00Z

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Attachments

Notification of managers' transaction - Anthony Rosenberg - 13 August 2026 RSU vest
Notification of managers' transaction - Christina Ackermann - 13 August 2026 RSU vest
Notification of managers' transaction - Arshad Khanani - 13 August 2026 RSU vest
Notification of managers' transaction - Robert Warner - 13 August 2026 RSU vest

Articles

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

2026-08-14T21:15:00Z

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy

Baylor Genetics Provides Notice of Data Security Incident

2026-08-14T21:00:00Z

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics recently identified a cybersecurity incident that impacted a limited portion of its information technology environment and certain individuals’ personal information. Upon...

GuideAI Health Corp. Announces Frankfurt Stock Exchange Symbol: ZN0

2026-08-14T21:00:00Z

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. ("GuideAI" or the "Company") (Cboe CA: GDAI) (FSE: ZN0) is pleased to announce its common shares are now posted on...

Optimi Health Establishes Discretionary Equity Facility

2026-08-14T20:55:00Z

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug...

PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027

2026-08-14T20:50:00Z

MINNEAPOLIS, MN, US, Aug. 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI,...

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2026-08-14T20:32:58Z

WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal...

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

2026-08-14T20:30:00Z

NEWTOWN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats...

Profound Medical Announces Management Change

2026-08-14T20:30:00Z

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures,...

Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

2026-08-14T20:28:58Z

Quarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments

Solana Company Reports Second Quarter 2026 Financial Results

2026-08-14T20:25:00Z

PHILADELPHIA, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to the...

Cerenome Reports Second Quarter 2026 Financial Results and Business Update

2026-08-14T20:15:00Z

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-08-14T20:05:00Z

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

4DMT Announces New Employment Inducement Grants

2026-08-14T20:05:00Z

EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to...

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-08-14T20:05:00Z

CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a...

BioStem Technologies to Present at the Sidoti MicroCap Conference

2026-08-14T20:05:00Z

POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization...

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

2026-08-14T20:05:00Z

-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval --ATLANTA, Aug. 14, 2026...

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-08-14T20:05:00Z

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H...

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

2026-08-14T20:05:00Z

BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results...

Precipio Announces Q2-2026 Financial Results

2026-08-14T20:00:00Z

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

2026-08-14T19:47:06Z

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its...

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

2026-08-14T19:15:00Z

MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat...